SPEVIGO® granted Breakthrough Therapy Designation in the U.S. for the prevention of generalized pustular psoriasis flares
Based on results from the EFFISAYIL™ 2 trial, which met its primary and key secondary endpoints for the prevention of generalized pustular psoriasis (GPP) flares1,2,3 Designation granted in recognition of the severe physical and mental health impact of flares

